NASDAQ:CLGN CollPlant Biotechnologies Q1 2025 Earnings Report $1.82 0.00 (0.00%) Closing price 03:58 PM EasternExtended Trading$1.82 +0.00 (+0.27%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CollPlant Biotechnologies EPS ResultsActual EPS-$0.13Consensus EPS -$0.37Beat/MissBeat by +$0.24One Year Ago EPSN/ACollPlant Biotechnologies Revenue ResultsActual Revenue$2.06 millionExpected Revenue$9.76 millionBeat/MissMissed by -$7.70 millionYoY Revenue GrowthN/ACollPlant Biotechnologies Announcement DetailsQuarterQ1 2025Date6/4/2025TimeBefore Market OpensConference Call DateWednesday, May 28, 2025Conference Call Time9:30AM ETUpcoming EarningsCollPlant Biotechnologies' Q2 2025 earnings is scheduled for Tuesday, August 19, 2025, with a conference call scheduled on Wednesday, August 20, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) CollPlant Biotechnologies Earnings HeadlinesCollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial OperationsJuly 14 at 7:00 AM | prnewswire.comCollPlant Biotechnologies (NASDAQ:CLGN) Trading Up 2.1% - Should You Buy?July 12, 2025 | americanbankingnews.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.July 17 at 2:00 AM | Crypto 101 Media (Ad)CollPlant Biotechnologies Ltd. (CLGN) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comCollPlant shares rise on expanded partnership with STEMCELL TechnologiesJune 9, 2025 | msn.comCOLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIESJune 9, 2025 | prnewswire.comSee More CollPlant Biotechnologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CollPlant Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CollPlant Biotechnologies and other key companies, straight to your email. Email Address About CollPlant BiotechnologiesCollPlant Biotechnologies (NASDAQ:CLGN) is a regenerative medicine company pioneering the use of recombinant human collagen produced in tobacco plants. By harnessing proprietary plant molecular farming technology, CollPlant develops bioactive, biocompatible collagen-based materials for tissue repair and reconstruction. The company’s innovative platform offers a sustainable source of human collagen that avoids the risks and supply limitations associated with animal-derived products. The company’s flagship products include Vergenix™ Flowable and Vergenix™STR, advanced collagen matrices designed to support wound healing, soft tissue regeneration and aesthetic procedures. In parallel, CollPlant is advancing a pipeline of cross-linkable bioinks for 3D bioprinting applications in orthopedics, plastic surgery and organ engineering. These bioinks are formulated to promote cell attachment and tissue maturation, positioning CollPlant at the forefront of biofabrication technologies. Founded in 2007 and headquartered in Ness Ziona, Israel, CollPlant maintains operations in the United States to serve global markets. The company collaborates with leading medical device firms, pharmaceutical partners and research institutions to accelerate commercialization of its collagen-based solutions. Strategic alliances span Europe, Asia and North America, reflecting CollPlant’s commitment to addressing unmet clinical needs worldwide. Under the leadership of Chief Executive Officer Yehiel Tal and co-founder and Chief Science Officer Morad Jaber, CollPlant combines scientific expertise with industrial-scale manufacturing capabilities. The management team’s experience in biotechnology and regenerative medicine supports the company’s long-term vision of transforming patient care through scalable, high-performance collagen products.Written by Jeffrey Neal JohnsonView CollPlant Biotechnologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Citigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting Cycle Upcoming Earnings American Express (7/18/2025)HDFC Bank (7/18/2025)3M (7/18/2025)Southern Copper (7/18/2025)Charles Schwab (7/18/2025)Truist Financial (7/18/2025)NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
